Evaluating Brentuximab Vedotin for Adults with Hodgkin's Lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the effectiveness and safety of Brentuximab Vedotin (BV) in adults with Hodgkin's Lymphoma (HL) who are undergoing or are candidates for autologous stem cell transplantation (ASCT). Participants will receive BV as part of their standard treatment and will be monitored through regular clinic visits over a period of 24 months. The study will enroll approximately 70 participants and will collect data on their treatment outcomes in a real-world clinical setting. Participants will be divided into two cohorts based on their treatment phase: pre-ASCT and post-ASCT.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1\. Adult participant (aged greater than or equal to \[\>=18\] years) that underwent or are candidates for ASCT and were enrolled in BV HL NDP receiving treatment according to the Summary of Product Characteristics for Adcetris and NDP.

Exclusion Criteria:

1. Currently participates or plans to participate in any interventional clinical trial.
2. Any other reason that, in the Investigator's opinion, makes the participant unsuitable to participate in this study.

Where it's running

• Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu
  Wroclaw, Dolnoslskie, Poland Recruiting
• Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu
  Poznan, Greater Poland Voivodeship, Poland Recruiting
• Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy Oddzial w Krakowie
  Krakow, Lesser Poland Voivodeship, Poland Recruiting
• Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie
  Krakow, Lesser Poland Voivodeship, Poland Recruiting
• Centrum Onkologii Ziemi Lubelskiej im. sw. Jana z Dukli
  Lublin, Lublin Voivodeship, Poland Recruiting
• NU-MED Specjalistyczny Szpital Onkologiczny Tomaszow Mazowiecki
  Tomaszow Mazowiecki, Masovian Voivodeship, Poland Recruiting

Study contacts

• Study coordinator: Takeda Contact
• Email: medinfoUS@takeda.com
• Phone: +1-877-825-3327

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• New ways to diagnose lymphoma and multicentric Castleman disease in people living with HIV

  This study tests a quick, point-of-care nucleic acid test to help diagnose lymphoma and multicentric Castleman disease in people living with HIV in sub-Saharan Africa.

  Recruiting Indiana University · Lilongwe · NCT07793006

• JLM019 Injection in Adults with Advanced Cancers

  This study tests JLM019 Injection in adults with advanced solid tumors or relapsed/refractory lymphomas to see if it’s safe and tolerable.

  Recruiting Phase 1 Jecho Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality · NCT07623850

• Cord blood transplant for children and young adults with blood cancers.

  This study will test whether a cord blood transplant given as a first or second transplant can help children and young adults with leukemia, myelodysplasia, or lymphoma who lack a matched donor.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT07566377

• Nivolumab plus AVD for newly diagnosed early-stage non-bulky classical Hodgkin lymphoma in young patients

  This study tests whether nivolumab added to AVD can help children, teens, and young adults with newly diagnosed early-stage non-bulky Hodgkin lymphoma.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07551583

• Adaptive Proton Therapy for Pediatric Solid Tumors and Hodgkin Lymphoma

  This study tests a regular imaging approach to see if proton therapy plans for children with solid tumors or Hodgkin lymphoma should be updated during treatment.

  Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07514819

• Autologous CD45 base-edited stem cells plus CART-45 cells for relapsed or refractory hematologic cancers

  This phase 1 study tests whether a patient’s own edited stem cells and CART-45 cells can be given safely to treat relapsed or refractory B-cell and T-cell lymphomas and Hodgkin lymphoma.

  Recruiting Phase 1 University of Pennsylvania · Philadelphia, Pennsylvania · NCT07451054

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.